Novel Therapeutic Approaches in Multiple Myeloma: The Future of CAR T-Cells
Release Date: November 26, 2018
Expiration Date: November 26, 2019
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
Chimeric antigen receptor (CAR) T-cell therapies have been approved for some leukemias and lymphomas, but they are also being explored as a potential treatment option for multiple myeloma (MM). In this activity, Dr. Noopur Raje discusses the mechanism of action for CAR T-cell therapies in MM and the role of conditioning chemotherapy in CAR T-cell therapy. Dr. Raje also describes the efficacy and safety of emerging CAR T-cell therapies for the treatment of MM.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Define the mechanism of action of therapies that utilize CAR T-cells
- Describe the role of agents used for conditioning chemotherapy in CAR T-cell therapy
- Identify the efficacy and safety of emerging CAR T-cell therapies for the treatment of multiple myeloma
Novel Therapeutic Approaches in Multiple Myeloma: The Future of CAR T-Cells – Noopur Raje, MD
Instructions for Participation and Credit
This activity is eligible for credit through November 26, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University in India. She trained in internal medicine at Massachusetts General Hospital (MGH), and subsequently completed a fellowship in hematology and medical oncology in the joint Mass General-Brigham & Women’s-Dana-Farber program. She is a Professor of Medicine at Harvard Medical School and the Rita M. Kelley Chair in Oncology at MGH.
Dr. Raje is a physician scientist with a focus on the development of innovative therapies for multiple myeloma. As Director of the Center for Multiple Myeloma at the MGH Cancer Center, she leads a dedicated clinical team engaged in investigator-initiated, multicenter national and international clinical trials, all aimed at developing new promising therapies for this disease. She also leads translational efforts at MGH with her laboratory's efforts focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and whose targeting may result in improved therapeutic outcomes. Dr. Raje is the recipient of numerous awards including the Multiple Myeloma Senior Research Award, The Leukemia and Lymphoma Society Clinical Scholar Award and the Claflin Distinguished Scholar Award.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-046-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Noopur Raje has received honoraria as a consultant from Amgen Inc., Celgene Corporation, Onyx Pharmaceuticals, Inc., an Amgen subsidiary, and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.